Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT)

This is Archived Content. This content is available for historical purposes only. It may not reflect the current state of science or language from the National Institute on Drug Abuse (NIDA). View current information on nida.nih.gov.

This 2 stage study will investigate the effectiveness and safety of a combination pharmacotherapy for methamphetamine use disorder.  Stage 1 will include 20 participants with moderate or severe stimulant use disorder who will receive a monthly injection of extended-release depot naltrexone plus once-daily bupropion extended-release tablets for 8 weeks.  If Stage 1 data documents success in at least 3 “responder” study participants, Stage 2 will follow utilizing the same protocol as in Stage 1, to enroll an additional group of 29 participants.

CTN Protocol ID: 
CTN-0054
ClinicalTrials.gov ID: 

Principal Investigator(s)

Walter Ling, M.D.
Director
Integrated Substance Abuse Programs
University of California, Los Angeles
11075 Santa Monica Boulevard
Suite 200
Los Angeles, CA 90025
lwalter@ucla.edu

Participating Sites